Tuesday, 14 May 2019

NHS England, Biogen reach deal on pricey drug for deadly disorder

England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)